NCT05281003View on ClinicalTrials.gov

Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)

PHASE2RecruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

February 20, 2023

Primary Completion Date

September 1, 2023

Study Completion Date

September 1, 2026

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Pembrolizumab

Biological: Pembrolizumab 200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.

DRUG

Paclitaxel

Drug: Paclitaxel 150 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.

DRUG

Cisplatin

Drug: Cisplatin 80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.

Trial Locations (2)

200032

RECRUITING

Fudan University Cancer Center, Shanghai

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Fudan University

OTHER